Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- PIII Study of Idebenone Initiated for DMD: Takeda
September 14, 2009
- SymBio Will Go Public When Bendamustine Is Approved
September 7, 2009
- Gov't to Rush to Take Measures against New-Type Flu
September 7, 2009
- Price Settlement Rate as of June Shows Improvement to 80.5%
September 7, 2009
- Treatment Recommended in High-Risk Patients Even If Simple Test Result Is Negative
September 7, 2009
- BUSINESS NEWS IN BRIEF
September 7, 2009
- METI to Promote Healthcare Tourism
September 7, 2009
- Orapenem Fine Granules 10% for Children: Meiji Seika
September 7, 2009
- DPJ to Come to Power with Landslide Victory vs LDP
September 7, 2009
- 11 New Products, 7 APIs Recommended for NHI Price Listing
September 7, 2009
- Basen Recommended for Approval for Prevention of Type 2 Diabetes
September 7, 2009
- Cervarix Recommended for Approval
September 7, 2009
- REGULATORY NEWS IN BRIEF
September 7, 2009
- Takeda to Initiate Additional Trial for Alogliptin
September 7, 2009
- Astellas to Reshuffle Its Drug Discovery Research Functions
September 7, 2009
- Lilly Drops Arzoxifene Based on Initial PIII Data
September 7, 2009
- R&D NEWS IN BRIEF
September 7, 2009
- 8 APIs Recommended for Switching to OTC Status
September 7, 2009
- Olmetec's Brand Value Ranked No. 1 among ARBs: Nielsen, So-Net M3
September 7, 2009
- Generics Are Not the Same as Original Drugs: Hiroshima Pref. Med. Association
September 7, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…